First Time Loading...

Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 5.09 USD 1.6% Market Closed
Updated: May 1, 2024
Section:
 

Wall Street
Price Targets

AUPH Price Targets Summary
Aurinia Pharmaceuticals Inc

Wall Street analysts forecast AUPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUPH is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

AUPH Lowest Forecast
Wall Street Target
8.08 USD
59% Upside
AUPH Average Forecast
Wall Street Target
11.51 USD
126% Upside
AUPH Highest Forecast
Wall Street Target
15.75 USD
209% Upside
Lowest
Price Target
8.08 USD
59% Upside
Average
Price Target
11.51 USD
126% Upside
Highest
Price Target
15.75 USD
209% Upside
Aurinia Pharmaceuticals Inc Competitors:
Price Targets
KURN
Kuros Biosciences AG
209% Upside
IPSC
Century Therapeutics Inc
420% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
57% Upside
ABIO
ARCA Biopharma Inc
101% Upside
KURN
Kuros Biosciences AG
209% Upside
IPSC
Century Therapeutics Inc
420% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
57% Upside
ABIO
ARCA Biopharma Inc
101% Upside
PBYI
Puma Biotechnology Inc
13% Downside
S
SVE
Synthaverse SA
38% Upside
CIR
Circassia Group PLC
29% Upside
ORGO
Organogenesis Holdings Inc
110% Upside

Revenue
Forecast

Revenue Estimate
Aurinia Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Aurinia Pharmaceuticals Inc's revenue is 133%. The projected CAGR for the next 3 years is 29%.

133%
Past Growth
29%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Aurinia Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Aurinia Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
What are analyst estimates?

See Also

Summary
AUPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
AUPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AUPH stock valuation using valuation multiples.
Wall Street Estimates
AUPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AUPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AUPH's stock price target?
Price Target
11.51 USD

According to Wall Street analysts, the average 1-year price target for AUPH is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

What is Aurinia Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
29%

For the last 8 years the compound annual growth rate for Aurinia Pharmaceuticals Inc's revenue is 133%. The projected CAGR for the next 3 years is 29%.

ALPHA SPREAD
Join more than 133,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.